Oleksandr Nevzghoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Oleksandr Nevzghoda has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anatoly Nevzghoda
Lviv Medical University
4 shared publications - Ihor Haiduchok
Lviv Medical University
4 shared publications - Viktoriia Shapovalova
Private Scientific Institution "Scientific and Research University of Medical and Pharmaceutical Law
4 shared publications - Alina Osyntseva
Lviv Medical University
3 shared publications - Valerii Shapovalov
Private Scientific Institution "Scientific and Research University of Medical and Pharmaceutical Law
3 shared publications Lviv Medical Univesity
2 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Publishing house Uston Ltd in Анали Мечниковського Інституту
- No. 1
Differential Diagnostic and Therapeutic Tactics of Pleurisy in Pancreatitis and Hepatitis: ABC and ABC/VED Analysis of Pathogenetic Pharmacotherapy
Introduction. Pleurisy associated with pancreatitis and liver diseases is accompanied by malabsorption and deficiency of fat-soluble vitamins, which justifies the use of vitamin pathogenetic pharmacotherapy. At the same time, the structure of the pharmaceutical market of vitamin drugs may not meet real clinical needs, which requires pharmacoeconomic assessment. Purpose. Clinical and pharmaceutical justification of the use of vitamin pharmacotherapy in patients with exudative pleurisy on the background of pancreatitis and hepatitis based on the analysis of the frequency of prescriptions and integrated ABC/VED-analysis of the range of drugs. Materials and methods. A retrospective observational study of 398 patients with exudative pleurisy who underwent inpatient treatment was conducted. The frequency of prescribing vitamin A, vitamin D, vitamin E and vitamin K as part of complex pharmacotherapy was analyzed. The pharmaceutical analysis included a study of the range of vitamin drugs registered in Ukraine using structural ABC analysis, clinically oriented ABC analysis by frequency of prescriptions and VED classification. Results. Established that the range of fat-soluble vitamins is represented by 19 drugs, among which vitamin E drugs dominate (68.42% of positions). Clinical analysis showed that vitamin E was the most frequently prescribed active pharmaceutical ingredient in patients with pancreatogenic and hepatogenic pleurisy. Integrated ABC/VED analysis identified vitamin E drugs as the priority category AV, while vitamin D and vitamin A formed the BE group, and vitamin K - the CD group. A discrepancy between the structure of the pharmaceutical market and the real clinical need was revealed, which indicates the duplication of trade names of vitamin E preparations.
- 8 June 2026
- Published by Publishing house Uston Ltd in Анали Мечниковського Інституту
- No. 1
Open AccessDifferential Diagnostic and Therapeutic Tactics of Pleurisy in Pancreatitis and Hepatitis: ABC and ABC/VED Analysis of Pathogenetic Pharmacotherapy
Introduction. Pleurisy associated with pancreatitis and liver diseases is accompanied by malabsorption and deficiency of fat-soluble vitamins, which justifies the use of vitamin pathogenetic pharmacotherapy. At the same time, the structure of the pharmaceutical market of vitamin drugs may not meet real clinical needs, which requires pharmacoeconomic assessment. Purpose. Clinical and pharmaceutical justification of the use of vitamin pharmacotherapy in patients with exudative pleurisy on the background of pancreatitis and hepatitis based on the analysis of the frequency of prescriptions and integrated ABC/VED-analysis of the range of drugs. Materials and methods. A retrospective observational study of 398 patients with exudative pleurisy who underwent inpatient treatment was conducted. The frequency of prescribing vitamin A, vitamin D, vitamin E and vitamin K as part of complex pharmacotherapy was analyzed. The pharmaceutical analysis included a study of the range of vitamin drugs registered in Ukraine using structural ABC analysis, clinically oriented ABC analysis by frequency of prescriptions and VED classification. Results. Established that the range of fat-soluble vitamins is represented by 19 drugs, among which vitamin E drugs dominate (68.42% of positions). Clinical analysis showed that vitamin E was the most frequently prescribed active pharmaceutical ingredient in patients with pancreatogenic and hepatogenic pleurisy. Integrated ABC/VED analysis identified vitamin E drugs as the priority category AV, while vitamin D and vitamin A formed the BE group, and vitamin K - the CD group. A discrepancy between the structure of the pharmaceutical market and the real clinical need was revealed, which indicates the duplication of trade names of vitamin E preparations.
- Open Access
- 1 April 2026
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 6 (2) , 19-48
Differential Diagnostic and Therapeutic Tactics for Pleurisy of Various Etiologies (Review)
Pleurisy of various etiologies remains an urgent clinical problem of modern pulmonology and thoracic surgery due to the high incidence of pleural effusions, pleural empyema, a significant duration of hospitalization and the risk of severe complications. The complexity of the clinical picture, the variety of etiological factors and the need for timely differential diagnosis determine the need to systematize modern approaches to the diagnosis and treatment of these conditions. The purpose of the work was to review modern scientific sources on epidemiology, etiology, pathophysiology, diagnosis, and treatment of pleurisy of various etiologies. A review and content analysis of scientific publications of international and national sources devoted to the problem of pleurisy, pleural effusions and pleural empyema have been carried out. Clinical recommendations of professional medical societies, results of clinical, cohort and retrospective studies, systematic reviews, as well as publications related to pharmacotherapy, surgical treatment and pharmacoeconomic aspects of patient management are analyzed. An analysis of the literature showed that the most common causes of pleural effusions are bacterial pneumonia, malignant neoplasms, tuberculous pleurisy, heart failure and pulmonary embolism. The etiological structure of pleural infections is represented mainly by Staphylococcus aureus, streptococci, gram-negative bacteria, and anaerobic flora. The paper summarizes modern approaches to the diagnosis of pleural effusions, including clinical assessment, general clinical laboratory methods of examination, immunological examination methods, radiography, ultrasound diagnostics, computed tomography, thoraco- and video thoracoscopy, trastoracal puncture under the control of computed tomography, fibrobronchoscopy for limited exudative pleurisy, laboratory analysis of pleural fluid, laboratory analysis of sputum. The role of the latest biomarkers, in particular soluble urokinase plasminogen activator receptor and procalcitonin, in predicting the course of pleural infection and the choice of treatment tactics is considered. Modern recommendations for the treatment of pleural empyema are presented, which include antibiotic therapy, pleural drainage, intrapleural fibrinolytic therapy, as well as surgical methods, including video-assisted thoracoscopic surgery and decortication. Clinical cases, results of cohort studies and the prognostic value of the RAPID scale were analyzed. Special attention is paid to the pharmacoeconomic aspects of treatment, the use of ABC/VED analysis to optimize pharmacotherapy, as well as innovative approaches to the treatment of pleurisy, in particular halotherapy and extracorporeal blood hyperthermia. Data on the association of pleural infections with comorbid conditions such as liver disease, pancreatitis, and other systemic pathologies have also been summarized. The latest methods of halotherapy in the treatment of fibrinous and exudative pleurisy are considered. The latest methods with the use of intravenous administration of alcohol solutions in the treatment of covid pneumonia with pleuropneumofibrosis are presented. It has been proven that acute vasculitis is of leading importance in the development of covid pneumonia. Standards for the treatment of fibrinous and exudative pleurisy have been developed. Therefore, modern tactics of management of patients with pleurisy of various etiologies are based on early diagnosis, the complex use of instrumental imaging methods, and rational antibiotic therapy in combination with adequate drainage of the pleural cavity. Minimally invasive surgical methods, the use of modern biomarkers and immune markers, immunological diagnostic methods, and a personalized approach to therapy play an important role in improving treatment outcomes. Promising areas for further research are the introduction of innovative treatment methods, improvement of pharmacoeconomic models for optimizing pharmacotherapy and integration of a multidisciplinary approach to the management of patients with pleural infections.
- 1 April 2026
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 6 (2) , 19-48
Open AccessDifferential Diagnostic and Therapeutic Tactics for Pleurisy of Various Etiologies (Review)
Pleurisy of various etiologies remains an urgent clinical problem of modern pulmonology and thoracic surgery due to the high incidence of pleural effusions, pleural empyema, a significant duration of hospitalization and the risk of severe complications. The complexity of the clinical picture, the variety of etiological factors and the need for timely differential diagnosis determine the need to systematize modern approaches to the diagnosis and treatment of these conditions. The purpose of the work was to review modern scientific sources on epidemiology, etiology, pathophysiology, diagnosis, and treatment of pleurisy of various etiologies. A review and content analysis of scientific publications of international and national sources devoted to the problem of pleurisy, pleural effusions and pleural empyema have been carried out. Clinical recommendations of professional medical societies, results of clinical, cohort and retrospective studies, systematic reviews, as well as publications related to pharmacotherapy, surgical treatment and pharmacoeconomic aspects of patient management are analyzed. An analysis of the literature showed that the most common causes of pleural effusions are bacterial pneumonia, malignant neoplasms, tuberculous pleurisy, heart failure and pulmonary embolism. The etiological structure of pleural infections is represented mainly by Staphylococcus aureus, streptococci, gram-negative bacteria, and anaerobic flora. The paper summarizes modern approaches to the diagnosis of pleural effusions, including clinical assessment, general clinical laboratory methods of examination, immunological examination methods, radiography, ultrasound diagnostics, computed tomography, thoraco- and video thoracoscopy, trastoracal puncture under the control of computed tomography, fibrobronchoscopy for limited exudative pleurisy, laboratory analysis of pleural fluid, laboratory analysis of sputum. The role of the latest biomarkers, in particular soluble urokinase plasminogen activator receptor and procalcitonin, in predicting the course of pleural infection and the choice of treatment tactics is considered. Modern recommendations for the treatment of pleural empyema are presented, which include antibiotic therapy, pleural drainage, intrapleural fibrinolytic therapy, as well as surgical methods, including video-assisted thoracoscopic surgery and decortication. Clinical cases, results of cohort studies and the prognostic value of the RAPID scale were analyzed. Special attention is paid to the pharmacoeconomic aspects of treatment, the use of ABC/VED analysis to optimize pharmacotherapy, as well as innovative approaches to the treatment of pleurisy, in particular halotherapy and extracorporeal blood hyperthermia. Data on the association of pleural infections with comorbid conditions such as liver disease, pancreatitis, and other systemic pathologies have also been summarized. The latest methods of halotherapy in the treatment of fibrinous and exudative pleurisy are considered. The latest methods with the use of intravenous administration of alcohol solutions in the treatment of covid pneumonia with pleuropneumofibrosis are presented. It has been proven that acute vasculitis is of leading importance in the development of covid pneumonia. Standards for the treatment of fibrinous and exudative pleurisy have been developed. Therefore, modern tactics of management of patients with pleurisy of various etiologies are based on early diagnosis, the complex use of instrumental imaging methods, and rational antibiotic therapy in combination with adequate drainage of the pleural cavity. Minimally invasive surgical methods, the use of modern biomarkers and immune markers, immunological diagnostic methods, and a personalized approach to therapy play an important role in improving treatment outcomes. Promising areas for further research are the introduction of innovative treatment methods, improvement of pharmacoeconomic models for optimizing pharmacotherapy and integration of a multidisciplinary approach to the management of patients with pleural infections.
- Open Access
- 26 March 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 1,p. 36-40
Tuberculous Pleural Disease (Pleuritis, Empyema): Clinical Perspective on First-Line Antituberculosis Medicines and Manufacturer-Based Content Analysis
Tuberculous pleural lesions (exudative pleurisy, tuberculous empyema) remain an urgent clinical and social problem, especially in conditions of high comorbidity, consequences of COVID-19, migration processes, hostilities, and disruption of the organisation of drug supplies. Despite the effectiveness of first-line antituberculosis medicines (isoniazid, rifampicin, pyrazinamide, ethambutol), the effectiveness of treatment of pleural forms is determined not only by the pharmacological properties of drugs, but also by their availability, the availability of appropriate dosages, fixed combinations, paediatric forms and confirmed production quality. Most clinical guidelines are based on data on pulmonary forms of tuberculosis, which leads to a lack of direct evidence for pleural localisations and emphasises the importance of a structured analysis of the range of drugs by manufacturer. Objective — based on the modern evidence base, evaluate the clinical perspective and perform a manufacturer-oriented content analysis of the first-line antituberculosis medicines assortment (dosage forms, dosages, fixed combinations, registration status) for tuberculous pleural lesions (pleurisy, empyema), considering the effectiveness, safety, availability and continuity of treatment. Offer practical recommendations for clinicians (phthisiatrician, pulmonologist, family doctor), clinical pharmacist, healthcare manager, administration of the institution, protocol and formulary commission. Materials and methods. A manufacturer-oriented content analysis of first-line antituberculosis medicines registered and approved for medical use in Ukraine in 2023—2025 was carried out. Data from international and national clinical guidelines (World Health Organization, American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America, standards of the Ministry of Health of Ukraine), registration dossiers, official instructions for medical use and the State Register of Medicines were used. Good Manufacturing Practice (GMP) compliance, inclusion in national evidentiary documents, compliance with international recommendations were assessed. The grouping of drugs by manufacturers was carried out according to the Sturges’ formula; dosage forms, dosages, fixed-dose combinations, pediatric suitability and the availability of bioequivalence data were evaluated separately. Results and discussion. A full range of dosage forms and dosages of first-line antituberculosis medicines necessary for the implementation of standard treatment regimens for pleural forms of tuberculosis has been identified. Differences between manufacturers in the presence of fixed combinations, low-dose and paediatric forms have been established, which determines the different level of their clinical suitability. The significance of penetration of drugs into the pleural space and the risks of subtherapeutic concentrations of rifampicin and pyrazinamide have been shown, which emphasise the importance of observing full-fledged regimens without interruption. Algorithms for the correction of adverse reactions, concomitant therapy and principles of intensive and continuation phases are analysed. Four groups of manufacturers were formed according to a comprehensive assessment of quality, availability, and stability of supply. An assortment of 41 drugs relevant for different patient categories, including children, has been identified. Gaps in fixed combinations and certain dosages have been identified, which require formulary and logistical solutions. Conclusions. Manufacturer-oriented content analysis is an effective tool for optimising the pharmacotherapy of tuberculous pleural lesions, providing a structured assessment of the range of first-line antituberculosis medicines in terms of effectiveness, safety, availability of dosages and quality of production. The results obtained make it possible to form reasonable recommendations for TB doctors, clinical pharmacists, formulary and procurement commissions, considering the need for continuity of treatment, minimisation of risks of resistance and increased patient adherence. The study highlights the need for further clinical work aimed at optimising treatment regimens specifically for pleural forms of tuberculosis and the introduction of Therapeutic Drug Monitoring in at-risk groups.
- 26 March 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 1,p. 36-40
Open AccessTuberculous Pleural Disease (Pleuritis, Empyema): Clinical Perspective on First-Line Antituberculosis Medicines and Manufacturer-Based Content Analysis
Tuberculous pleural lesions (exudative pleurisy, tuberculous empyema) remain an urgent clinical and social problem, especially in conditions of high comorbidity, consequences of COVID-19, migration processes, hostilities, and disruption of the organisation of drug supplies. Despite the effectiveness of first-line antituberculosis medicines (isoniazid, rifampicin, pyrazinamide, ethambutol), the effectiveness of treatment of pleural forms is determined not only by the pharmacological properties of drugs, but also by their availability, the availability of appropriate dosages, fixed combinations, paediatric forms and confirmed production quality. Most clinical guidelines are based on data on pulmonary forms of tuberculosis, which leads to a lack of direct evidence for pleural localisations and emphasises the importance of a structured analysis of the range of drugs by manufacturer. Objective — based on the modern evidence base, evaluate the clinical perspective and perform a manufacturer-oriented content analysis of the first-line antituberculosis medicines assortment (dosage forms, dosages, fixed combinations, registration status) for tuberculous pleural lesions (pleurisy, empyema), considering the effectiveness, safety, availability and continuity of treatment. Offer practical recommendations for clinicians (phthisiatrician, pulmonologist, family doctor), clinical pharmacist, healthcare manager, administration of the institution, protocol and formulary commission. Materials and methods. A manufacturer-oriented content analysis of first-line antituberculosis medicines registered and approved for medical use in Ukraine in 2023—2025 was carried out. Data from international and national clinical guidelines (World Health Organization, American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America, standards of the Ministry of Health of Ukraine), registration dossiers, official instructions for medical use and the State Register of Medicines were used. Good Manufacturing Practice (GMP) compliance, inclusion in national evidentiary documents, compliance with international recommendations were assessed. The grouping of drugs by manufacturers was carried out according to the Sturges’ formula; dosage forms, dosages, fixed-dose combinations, pediatric suitability and the availability of bioequivalence data were evaluated separately. Results and discussion. A full range of dosage forms and dosages of first-line antituberculosis medicines necessary for the implementation of standard treatment regimens for pleural forms of tuberculosis has been identified. Differences between manufacturers in the presence of fixed combinations, low-dose and paediatric forms have been established, which determines the different level of their clinical suitability. The significance of penetration of drugs into the pleural space and the risks of subtherapeutic concentrations of rifampicin and pyrazinamide have been shown, which emphasise the importance of observing full-fledged regimens without interruption. Algorithms for the correction of adverse reactions, concomitant therapy and principles of intensive and continuation phases are analysed. Four groups of manufacturers were formed according to a comprehensive assessment of quality, availability, and stability of supply. An assortment of 41 drugs relevant for different patient categories, including children, has been identified. Gaps in fixed combinations and certain dosages have been identified, which require formulary and logistical solutions. Conclusions. Manufacturer-oriented content analysis is an effective tool for optimising the pharmacotherapy of tuberculous pleural lesions, providing a structured assessment of the range of first-line antituberculosis medicines in terms of effectiveness, safety, availability of dosages and quality of production. The results obtained make it possible to form reasonable recommendations for TB doctors, clinical pharmacists, formulary and procurement commissions, considering the need for continuity of treatment, minimisation of risks of resistance and increased patient adherence. The study highlights the need for further clinical work aimed at optimising treatment regimens specifically for pleural forms of tuberculosis and the introduction of Therapeutic Drug Monitoring in at-risk groups.
- 18 March 2026
- Published by Shapovalov Scientific Publishing OU (Publications)
Ethical Issues in Healthcare: Gender Equality, Prevention of Discrimination, Bioethics, Confidentiality, Impact of War, Empathy
The scientific and theoretical, educational and methodical manual is devoted to a comprehensive consideration of medical and pharmaceutical ethics, bioethics, deontology, patient rights and legal principles of professional activity in the field of healthcare. The publication systematizes the theoretical foundations of ethics, reveals the principles of humanism, respect, confidentiality, informed consent, and professional responsibility, analyzes international and national regulatory documents regulating the ethical behavior of medical and pharmaceutical workers. Special attention is paid to practical aspects of professional interaction in the doctor-patient-pharmacist triad, algorithms for ethical decision-making, analysis of typical conflict and discriminatory situations, the limits of confidentiality and legal grounds for processing medical information in the conditions of digitalization of the healthcare system and martial law. The manual contains interactive elements, cases for discussion, ethical response models and recommendations for the development of a specialist's ethical culture. The purpose of the publication is to increase competence in ethical issues that are mandatory areas of continuous professional development in the healthcare sector, in particular, the formation of empathy, prevention of professional burnout, strengthening professional responsibility and development of ethical communication skills. The manual is intended for medical, pharmaceutical specialties, specialties of professionals and specialists in the healthcare sector, and can also be used in the system of undergraduate and postgraduate education, during seminars, trainings, and programs of continuous professional development.
- 18 March 2026
- Published by Shapovalov Scientific Publishing OU (Publications)
Ethical Issues in Healthcare: Gender Equality, Prevention of Discrimination, Bioethics, Confidentiality, Impact of War, Empathy
The scientific and theoretical, educational and methodical manual is devoted to a comprehensive consideration of medical and pharmaceutical ethics, bioethics, deontology, patient rights and legal principles of professional activity in the field of healthcare. The publication systematizes the theoretical foundations of ethics, reveals the principles of humanism, respect, confidentiality, informed consent, and professional responsibility, analyzes international and national regulatory documents regulating the ethical behavior of medical and pharmaceutical workers. Special attention is paid to practical aspects of professional interaction in the doctor-patient-pharmacist triad, algorithms for ethical decision-making, analysis of typical conflict and discriminatory situations, the limits of confidentiality and legal grounds for processing medical information in the conditions of digitalization of the healthcare system and martial law. The manual contains interactive elements, cases for discussion, ethical response models and recommendations for the development of a specialist's ethical culture. The purpose of the publication is to increase competence in ethical issues that are mandatory areas of continuous professional development in the healthcare sector, in particular, the formation of empathy, prevention of professional burnout, strengthening professional responsibility and development of ethical communication skills. The manual is intended for medical, pharmaceutical specialties, specialties of professionals and specialists in the healthcare sector, and can also be used in the system of undergraduate and postgraduate education, during seminars, trainings, and programs of continuous professional development.
- Open Access
- 1 January 2026
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 6 (1) , 16-38
Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health
The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.
- 1 January 2026
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 6 (1) , 16-38
Open AccessClinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health
The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.
- Open Access
- 31 October 2025
- Published by Shapovalov Scientific Publishing OU (Publications)
Extracorporeal Blood Hyperthermia in the Treatment of Exudative Pleuritis and Pleural Empyema: Medical and Legal Components
Extracorporeal blood hyperthermia was first used in the treatment of exudative pleurisy and pleural empyema. Proven that hyperthermia is highly effective in exudative pleurisy and pleural empyema. An apparatus for extracorporeal blood hyperthermia was first proposed. The medical and legal components of the use of extracorporeal blood hyperthermia in a closed circuit for the treatment of exudative pleurisy and pleural empyema with anti-inflammatory purposes were first described. The legal grounds, requirements, and procedures for the safe and proper use of extracorporeal blood hyperthermia in clinical practice of surgery were given.
- 31 October 2025
- Published by Shapovalov Scientific Publishing OU (Publications)
Open AccessExtracorporeal Blood Hyperthermia in the Treatment of Exudative Pleuritis and Pleural Empyema: Medical and Legal Components
Extracorporeal blood hyperthermia was first used in the treatment of exudative pleurisy and pleural empyema. Proven that hyperthermia is highly effective in exudative pleurisy and pleural empyema. An apparatus for extracorporeal blood hyperthermia was first proposed. The medical and legal components of the use of extracorporeal blood hyperthermia in a closed circuit for the treatment of exudative pleurisy and pleural empyema with anti-inflammatory purposes were first described. The legal grounds, requirements, and procedures for the safe and proper use of extracorporeal blood hyperthermia in clinical practice of surgery were given.
- Open Access
- 1 October 2025
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 5 (4) , 92-106
Pleural Diseases and Endocrine Disorders: Modern Approaches to the Treatment of Comorbid Conditions
The article discusses the relationship between diseases of the pleura (pleural effusion, pleurisy, empyema) and endocrine disorders, in particular hypothyroidism, as a potential modifying factor in the course of pleural pathology. An analysis of modern literature sources on the pathogenetic mechanisms of pleural effusion formation in thyroid dysfunction, clinical features, diagnostic approaches and effectiveness of levothyroxine replacement therapy has been carried out. It has been found that some patients with hypothyroidism develop pleural effusions, which regress after reaching euthyroid. The paper describes epidemiological, diagnostic, clinical, pharmacological and organizational gaps in the study of this comorbid condition. The authors proposed an algorithm for the initial diagnosis of pleural effusions and routing of patients, taking into account the determination of thyroid status. ABC/VED analysis of drugs used in the pharmacotherapy of hypothyroid-associated diseases of the pleura was performed. Levothyroxine has been shown to be a key etiotropic agent, and timely hormonal correction reduces the need for invasive procedures and improves clinical outcomes. The importance of a multidisciplinary approach to diagnosis and treatment, which combines pulmonological, endocrinological and clinical-pharmacological aspects, is emphasized.
- 1 October 2025
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 5 (4) , 92-106
Open AccessPleural Diseases and Endocrine Disorders: Modern Approaches to the Treatment of Comorbid Conditions
The article discusses the relationship between diseases of the pleura (pleural effusion, pleurisy, empyema) and endocrine disorders, in particular hypothyroidism, as a potential modifying factor in the course of pleural pathology. An analysis of modern literature sources on the pathogenetic mechanisms of pleural effusion formation in thyroid dysfunction, clinical features, diagnostic approaches and effectiveness of levothyroxine replacement therapy has been carried out. It has been found that some patients with hypothyroidism develop pleural effusions, which regress after reaching euthyroid. The paper describes epidemiological, diagnostic, clinical, pharmacological and organizational gaps in the study of this comorbid condition. The authors proposed an algorithm for the initial diagnosis of pleural effusions and routing of patients, taking into account the determination of thyroid status. ABC/VED analysis of drugs used in the pharmacotherapy of hypothyroid-associated diseases of the pleura was performed. Levothyroxine has been shown to be a key etiotropic agent, and timely hormonal correction reduces the need for invasive procedures and improves clinical outcomes. The importance of a multidisciplinary approach to diagnosis and treatment, which combines pulmonological, endocrinological and clinical-pharmacological aspects, is emphasized.
- Open Access
- 11 September 2025
- Published by Shapovalov Scientific Publishing OU (Publications)
Pharmacoeconomic Studies of the Feasibility of Using Certain Groups of Drugs in Diseases of the Chest Organs
The scientific and methodological recommendations present modern approaches to conducting ABC/VED analysis as a tool for pharmacoeconomic assessment of the feasibility of using drugs for diseases of the chest organs. The publication contains methodological principles of analysis, algorithms for classifying drugs by economic significance and clinical priority, as well as results of studies of individual pharmacotherapeutic groups used for pneumonia, tuberculosis, broncho-obstructive conditions, pulmonary hypertension, and concomitant pathologies. Special attention is paid to electrolytes, vasodilators, analgesics, hepatotropic agents and vitamins as part of complex pharmacotherapy for diseases of the chest organs. A multidisciplinary approach to the study of risks and errors in the system of legal relations "doctor-patient-pharmacist-lawyer" is considered, considering clinical and pharmacological, legal, forensic and pharmaceutical aspects in pulmonology. Practical recommendations are provided for the implementation of ABC/VED analysis in the activities of health care institutions to optimize medical and pharmaceutical care, increase the efficiency of the use of financial resources and minimize risks. Recommended for health care professionals, doctors, clinical pharmacists, pharmacists, heads of pharmacy institutions, health care organizers, scientists, and scientific and pedagogical workers for use in scientific, educational, and practical activities.
- 11 September 2025
- Published by Shapovalov Scientific Publishing OU (Publications)
Open AccessPharmacoeconomic Studies of the Feasibility of Using Certain Groups of Drugs in Diseases of the Chest Organs
The scientific and methodological recommendations present modern approaches to conducting ABC/VED analysis as a tool for pharmacoeconomic assessment of the feasibility of using drugs for diseases of the chest organs. The publication contains methodological principles of analysis, algorithms for classifying drugs by economic significance and clinical priority, as well as results of studies of individual pharmacotherapeutic groups used for pneumonia, tuberculosis, broncho-obstructive conditions, pulmonary hypertension, and concomitant pathologies. Special attention is paid to electrolytes, vasodilators, analgesics, hepatotropic agents and vitamins as part of complex pharmacotherapy for diseases of the chest organs. A multidisciplinary approach to the study of risks and errors in the system of legal relations "doctor-patient-pharmacist-lawyer" is considered, considering clinical and pharmacological, legal, forensic and pharmaceutical aspects in pulmonology. Practical recommendations are provided for the implementation of ABC/VED analysis in the activities of health care institutions to optimize medical and pharmaceutical care, increase the efficiency of the use of financial resources and minimize risks. Recommended for health care professionals, doctors, clinical pharmacists, pharmacists, heads of pharmacy institutions, health care organizers, scientists, and scientific and pedagogical workers for use in scientific, educational, and practical activities.
- Open Access
- 1 July 2025
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 3 (5) , 93-106
Diagnosis and Treatment of Pleural Cavity Empyema
Pleural empyema remains a serious medical problem, accompanied by a high incidence, a complex clinical course and significant mortality. The article presents the results of a multi-year study of 556 patients who were treated at the Pulmonary Health Center of Lviv in 2017–2024. The clinical forms, etiology, radiological and ultrasound signs of empyema are analyzed, as well as the applied methods of diagnosis and treatment: pleural punctures, drainage, antibiotic therapy, thoracoplasty, decortication. Indications for surgical interventions and features of the course of pleural empyema are given. The importance of early diagnosis, a personalized approach to treatment and prevention of medical errors in the context of the development of telemedicine is emphasized. This large, single-center cohort reflects routine clinical practice in a high-volume referral facility, offering robust, generalizable evidence for settings with constrained resources and rising antimicrobial resistance. By integrating radiologic–sonographic criteria with procedural outcomes, the work clarifies triage, optimizes timing of intervention, and guides antibiotic stewardship, supporting standardized care pathways and telemedicine-enabled follow-up. The findings have immediate implications for guideline refinement, training of multidisciplinary teams, and reduction of complications and length of stay ultimately improving survival, preserving lung function, and enhancing patients’ quality of life. The results obtained may be useful for improving the tactics of managing patients with pleural empyema and reducing the risk of chronicity of the disease.
- 1 July 2025
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 3 (5) , 93-106
Open AccessDiagnosis and Treatment of Pleural Cavity Empyema
Pleural empyema remains a serious medical problem, accompanied by a high incidence, a complex clinical course and significant mortality. The article presents the results of a multi-year study of 556 patients who were treated at the Pulmonary Health Center of Lviv in 2017–2024. The clinical forms, etiology, radiological and ultrasound signs of empyema are analyzed, as well as the applied methods of diagnosis and treatment: pleural punctures, drainage, antibiotic therapy, thoracoplasty, decortication. Indications for surgical interventions and features of the course of pleural empyema are given. The importance of early diagnosis, a personalized approach to treatment and prevention of medical errors in the context of the development of telemedicine is emphasized. This large, single-center cohort reflects routine clinical practice in a high-volume referral facility, offering robust, generalizable evidence for settings with constrained resources and rising antimicrobial resistance. By integrating radiologic–sonographic criteria with procedural outcomes, the work clarifies triage, optimizes timing of intervention, and guides antibiotic stewardship, supporting standardized care pathways and telemedicine-enabled follow-up. The findings have immediate implications for guideline refinement, training of multidisciplinary teams, and reduction of complications and length of stay ultimately improving survival, preserving lung function, and enhancing patients’ quality of life. The results obtained may be useful for improving the tactics of managing patients with pleural empyema and reducing the risk of chronicity of the disease.
- Open Access
- 29 May 2025
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 2,p. 5-10
Pathogenetic and Pathomorphological Aspects of Pulmonary Tissue Damage in COVID-19 as a Manifestation of Vasculitis
Objective — to determine the features of pathogenesis in patients with the pulmonary form of SARS-CoV-2. To establish, based on clinical examination data and electron microscopy, that vasculitis of the respiratory system is the main pathophysiological and pathomorphological factor in lung tissue damage in COVID-19. Materials and methods. A total of 692 patients aged 18 to 73 years with severe SARS-CoV-2 were examined. The control group consisted of 50 patients (25 women and 25 men) aged 25—70 years with a moderately severe clinical course of SARS-CoV-2. 58 patients underwent immunological tests, which included the study of O-lymphocytes and D-lymphocytes, circulating small and large immune complexes. A group of 30 people who died of COVID-19 pneumonia underwent a pathohistological examination of tissue samples. A group of 10 people who died of COVID-19 pneumonia underwent electron microscopic examination of tissue samples. Results and discussion. Immunological examination revealed an increase in the number of O-lymphocytes (53.3 ± 1.3), an increase in the number of D-lymphocytes (4.9 ± 0.7), which highlights the impairment of T-cells of immunity; the predominance of the total mass of an increased level of small CICs (71.3 ± 2.5), which indicates a particularly «malignant» autoimmune component with damage to the connective tissue structure, primarily the vessels of the lungs, and therefore the vessels of epithelial organs, and an increase in the number of large CICs, which explains the material basis of allergic complications that accompany the severe course of SARS. Ultrastructural electron microscopic examination of the respiratory tract of patients who died from respiratory failure in COVID-19 revealed the development of degenerative changes in the capillaries and endothelium, characterised by the expansion of the tubules of the granular endoplasmic reticulum, the destruction of ribosomes, the appearance of vacuoles in the cytoplasm surrounded by a double-contour membrane and containing small virion-like bodies, the basement membrane of haemocapillaries was heterogeneously thickened. The development of venulitis was recorded, which is characterised by the accumulation of neutrophils in the vessel wall, pronounced degenerative changes in the endothelium, accompanied by the destruction of cytoplasmic organelles, vacuolisation of the cytoplasm and its heterogeneous osmophilia, the appearance of heterogeneous microvilli on the lumenal surface of the endothelium, and heterogeneous thickening of the cytoplasmic membrane. Ultrastructural changes in the vascular endothelium in COVID-19 indicate the primary occurrence of acute vasculitis as a pathogenetic dominant in COVID-19 pneumonia. Conclusions. Clinical manifestations and ultrastructural pathomorphological studies conducted by us reliably indicate that the primary pathogenetic basis of atypical pneumonia in COVID-19 syndrome is the occurrence of acute vasculitis with predominant damage to the vessels of the pulmonary system. The «malignant» course of COVID-19 syndrome involves the transformation of acute vasculitis into systemic vasculitis with subsequent unpredictable damage to a number of systems (respiratory, cardiovascular, hepatobiliary, genitourinary).
- 29 May 2025
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 2,p. 5-10
Open AccessPathogenetic and Pathomorphological Aspects of Pulmonary Tissue Damage in COVID-19 as a Manifestation of Vasculitis
Objective — to determine the features of pathogenesis in patients with the pulmonary form of SARS-CoV-2. To establish, based on clinical examination data and electron microscopy, that vasculitis of the respiratory system is the main pathophysiological and pathomorphological factor in lung tissue damage in COVID-19. Materials and methods. A total of 692 patients aged 18 to 73 years with severe SARS-CoV-2 were examined. The control group consisted of 50 patients (25 women and 25 men) aged 25—70 years with a moderately severe clinical course of SARS-CoV-2. 58 patients underwent immunological tests, which included the study of O-lymphocytes and D-lymphocytes, circulating small and large immune complexes. A group of 30 people who died of COVID-19 pneumonia underwent a pathohistological examination of tissue samples. A group of 10 people who died of COVID-19 pneumonia underwent electron microscopic examination of tissue samples. Results and discussion. Immunological examination revealed an increase in the number of O-lymphocytes (53.3 ± 1.3), an increase in the number of D-lymphocytes (4.9 ± 0.7), which highlights the impairment of T-cells of immunity; the predominance of the total mass of an increased level of small CICs (71.3 ± 2.5), which indicates a particularly «malignant» autoimmune component with damage to the connective tissue structure, primarily the vessels of the lungs, and therefore the vessels of epithelial organs, and an increase in the number of large CICs, which explains the material basis of allergic complications that accompany the severe course of SARS. Ultrastructural electron microscopic examination of the respiratory tract of patients who died from respiratory failure in COVID-19 revealed the development of degenerative changes in the capillaries and endothelium, characterised by the expansion of the tubules of the granular endoplasmic reticulum, the destruction of ribosomes, the appearance of vacuoles in the cytoplasm surrounded by a double-contour membrane and containing small virion-like bodies, the basement membrane of haemocapillaries was heterogeneously thickened. The development of venulitis was recorded, which is characterised by the accumulation of neutrophils in the vessel wall, pronounced degenerative changes in the endothelium, accompanied by the destruction of cytoplasmic organelles, vacuolisation of the cytoplasm and its heterogeneous osmophilia, the appearance of heterogeneous microvilli on the lumenal surface of the endothelium, and heterogeneous thickening of the cytoplasmic membrane. Ultrastructural changes in the vascular endothelium in COVID-19 indicate the primary occurrence of acute vasculitis as a pathogenetic dominant in COVID-19 pneumonia. Conclusions. Clinical manifestations and ultrastructural pathomorphological studies conducted by us reliably indicate that the primary pathogenetic basis of atypical pneumonia in COVID-19 syndrome is the occurrence of acute vasculitis with predominant damage to the vessels of the pulmonary system. The «malignant» course of COVID-19 syndrome involves the transformation of acute vasculitis into systemic vasculitis with subsequent unpredictable damage to a number of systems (respiratory, cardiovascular, hepatobiliary, genitourinary).